Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEF0117 PK Interaction with Smoked Cannabis
NCT06395688Phase 1Withdrawn
- Sponsor
- Aelis Farma
- Start
- Dec 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of aef0117 in cannabis use disorder (CUD), sponsored by Aelis Farma. Primary endpoint: Maximal plasma concentration of THC and AEF0117 at Day 8. Planned start Dec 2025; status: withdrawn.
02
Drugs
aef0117
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT06395688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06395688.